进行性核上性麻痹(PSP)是一种罕见的,神经退行性运动障碍。连同多系统萎缩(MSA),路易体痴呆(DLB),和皮质基底变性(CBD),PSP形成一组非典型帕金森病。最新的诊断标准,2017年由运动障碍协会出版,将PSP诊断分类为已定义的,可能,以及基于临床检查的可能类别。然而,没有单一的测试是特异性和敏感的这种疾病。微小核糖核酸(miRNA)是有前途的分子,特别是在缺乏适当诊断和治疗工具的疾病的情况下,这支持探索它们在PSP中的作用。我们旨在系统回顾目前有关miRNAs在PSP中的作用的知识。这项研究在开放科学框架注册中心注册,该协议可以在线获得。初级原始研究,临床和临床前,包括用英语编写并评估PSP中的miRNA。系统审查,荟萃分析,reviews,病例报告,给编辑的信,评论,会议摘要,准则/声明,专家意见,预印本,和书籍章节被排除在外。搜索了以下五个数据库:Embase,MedlineUltimate,PubMed,Scopus,和WebofScience。每个数据库最后一次搜索是在2024年6月18日。最终,包括9项与所讨论区域相关的原始研究.未评估偏倚风险。选定的研究表明,miRNA可能被认为是PSP中有前途的生物标志物。然而,miRNA在PSP发病机制中的确切参与仍有待确定。发现PSP患者中几种microRNA失调。这适用于脑组织和脑脊液CSF或血液等液体。发现一些miRNA可能有助于区分PSP患者,PD患者,和健康的个体。尽管已经发现了一些相关性和改变,这个领域需要更多的研究。microRNAs是令人兴奋和有前途的小分子,以及他们对许多疾病的调查,包括PSP,可能导致重大发现。
Progressive supranuclear palsy (PSP) is a rare, neurodegenerative movement disorder. Together with multiple system atrophy (MSA), Dementia with Lewy bodies (DLB), and corticobasal degeneration (CBD), PSP forms a group of atypical parkinsonisms. The latest diagnostic criteria, published in 2017 by the Movement Disorders Society, classify PSP diagnosis into defined, probable, and possible categories based on clinical examination. However, no single test is specific and sensitive for this disease. Microribonucleic acids (miRNAs) are promising molecules, particularly in the case of diseases that lack appropriate diagnostic and treatment tools, which supports exploring their role in PSP. We aimed to systematically review the current knowledge about the role of miRNAs in PSP. This study was registered in the Open Science Framework Registry, and the protocol is available online. Primary original studies, both clinical and preclinical, written in English and assessing miRNAs in PSP were included. Systematic reviews, meta-analyses, reviews, case reports, letters to editors, commentaries, conference abstracts, guidelines/statements, expert opinions, preprints, and book chapters were excluded. The following five databases were searched: Embase, Medline Ultimate, PubMed, Scopus, and Web of Science. Each database was last searched on 18 June 2024. Eventually, nine original studies relevant to the discussed area were included. The risk of bias was not assessed. The selected research suggests that miRNAs may be considered promising biomarkers in PSP. However, the exact involvement of miRNAs in the pathogenesis of PSP is still to be determined. Several microRNAs were found to be dysregulated in patients with PSP. This applies to both brain tissue and fluids like cerebrospinal fluid CSF or blood. Several miRNAs were found that could potentially be helpful in differentiating among PSP patients, PD patients, and healthy individuals. Although some correlations and alterations have already been found, this field requires much more research. MicroRNAs are exciting and promising small molecules, and their investigation into many diseases, including PSP, may lead to significant discoveries.